BACKGROUND: We previously demonstrated that the @entity1811 ( @entity1811 ) inhibitor, @entity4688 , prevents the age-related impairment of endothelium-dependent hyperpolarization and relaxation mediated by endothelium-derived hyperpolarizing factor (EDHF). OBJECTIVE: To test whether @entity11154 antagonists would also improve age-related @entity409 . METHODS: Normotensive @entity35 -Kyoto (WKY) @entity35 were treated for 3 months with either the AT1 receptor antagonist, @entity22666 (3.5 mg/kg per day; @entity1564 group), or the @entity1811 inhibitor, @entity4688 (20 mg/kg per day; @entity4688 group), from 9 to 12 months of age. Untreated 12-month-old WKY @entity35 (old group) served as controls (n = 7-12). RESULTS: The two treatments decreased systolic blood pressure comparably. EDHF-mediated hyperpolarization in response to @entity934 ( @entity1617 ; 10(-5) mol/l) in the presence of @entity1063 in mesenteric arteries was improved in both the @entity1564 and @entity4688 groups to a similar extent compared with the old group ( @entity1564 group, -24 +/- 3 mV; @entity4688 group, -21 +/- 2 mV; old group, -13 +/- 2 mV). EDHF-mediated relaxation was similarly improved in the @entity1564 and @entity4688 groups (maximum relaxation: @entity1564 group, 70 +/- 7%; @entity4688 group, 63 +/- 8%; old group, 33 +/- 9%). Hyperpolarization and relaxation responses to levcromakalim, an @entity855 -sensitive K+-channel opener, were similar in all groups. CONCLUSIONS: These findings suggest that the AT1 receptor antagonist is as effective as the @entity1811 inhibitor in improving the age-related decline in EDHF-mediated hyperpolarization and relaxation in normotensive @entity35 . Thus AT1 receptor antagonists might serve as novel tools with which to prevent @entity409 associated with aging.

Angiotensin II receptor antagonist improves age-related XXXX .

@entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine'] @entity35 :: ('10116', 'Species') :: ['Wistar', 'rats'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity1564 :: ('MESH:C081643', 'Chemical') :: ['candesartan'] @entity1617 :: ('CHEBI:22614', 'Chemical') :: ['ACh'] @entity1811 :: ('24310(Tax:10116)', 'Gene') :: ['ACE', 'angiotensin converting enzyme'] @entity22666 :: ('MESH:C077793', 'Chemical') :: ['candesartan cilexetil'] @entity11154 :: ('81638(Tax:10116)', 'Gene') :: ['angiotensin II type 1 (AT1) receptor'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['ATP'] @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']
@entity409 :: (MESH:D008107,Disease) :: ['endothelial dysfunction']
